Real-world analysis of the efficacy and safety of lorlatinib in ALK-positive non-small cell lung cancer patients in China.

Tian G, Nie J, Dai L, Hu W, Zhang J, Wu D, Ma X, Chen X, Han S, Han J, Zhang Z, Long J, Zhao X, Fang J

Open source

DOI: 10.3389/fonc.2025.1577607
Published: 2025
Container: Frontiers in oncology
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fonc.2025.1577607,
  title = {Real-world analysis of the efficacy and safety of lorlatinib in ALK-positive non-small cell lung cancer patients in China.},
  author = {Tian G and Nie J and Dai L and Hu W and Zhang J and Wu D and Ma X and Chen X and Han S and Han J and Zhang Z and Long J and Zhao X and Fang J},
  year = {2025},
  journal = {Frontiers in oncology},
  doi = {10.3389/fonc.2025.1577607},
  url = {https://doi.org/10.3389/fonc.2025.1577607}
}

RIS

TY  - JOUR
TI  - Real-world analysis of the efficacy and safety of lorlatinib in ALK-positive non-small cell lung cancer patients in China.
AU  - Tian G
AU  - Nie J
AU  - Dai L
AU  - Hu W
AU  - Zhang J
AU  - Wu D
AU  - Ma X
AU  - Chen X
AU  - Han S
AU  - Han J
AU  - Zhang Z
AU  - Long J
AU  - Zhao X
AU  - Fang J
PY  - 2025
JO  - Frontiers in oncology
DO  - 10.3389/fonc.2025.1577607
UR  - https://doi.org/10.3389/fonc.2025.1577607
ER  -

APA

G, T., J, N., L, D., W, H., J, Z., D, W., X, M., X, C., S, H., J, H., Z, Z., J, L., X, Z., & J, F. (2025). Real-world analysis of the efficacy and safety of lorlatinib in ALK-positive non-small cell lung cancer patients in China.. Frontiers in oncology. https://doi.org/10.3389/fonc.2025.1577607

Source records

pubmed · retrieved 2026-09-25T09:13:08.247Z
europe-pmc · retrieved 2026-09-25T09:13:08.243Z
doaj · retrieved 2026-09-25T09:13:08.238Z